Gelonghui, November 4th | Blackstone Life Sciences has agreed to provide Merck & Co. with $700 million to support the development of an experimental cancer drug named sacituzumab tirumotecan. Merck is currently conducting 15 Phase III clinical trials on the drug, covering six types of tumors, including breast cancer, endometrial cancer, and lung cancer. Under the agreement, Blackstone will be eligible to receive a portion of the royalties from the drug, while Merck will retain decision-making authority and control over the drug’s development, manufacturing, and commercialization.
Merck receives $700 million investment from Blackstone Life Sciences for the development of cancer drugs.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Market Insights
Hot Stock Hot Stock
Top HK stocks viewed in the last 24 hours, capturing market sentiment and key capital flow insights. Top HK stocks viewed in the last 24 hours, capturing market sentiment and key capital flow insights.
View More
Hot Topics
Monthly Market Outlook: Peak Earnings Season! How to Navigate November?
In October, the U.S. stock market once again achieved a remarkable increase, with the three major indices hitting new record highs! Looking
年頭旺到年尾
Nov 3 06:28
October 31 review ..